Kevan Herold
Affiliations: | Yale University, New Haven, CT |
Area:
Medicine and Surgery, Cell BiologyGoogle:
"Kevan Herold"
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Abdel-Karim TR, Hodges JS, Herold KC, et al. (2024) Peri-Transplant Inflammation and Long-Term Diabetes Outcomes Were Not Impacted by Either Etanercept or Alpha-1-Antitrypsin Treatment in Islet Autotransplant Recipients. Transplant International : Official Journal of the European Society For Organ Transplantation. 37: 12320 |
Latres E, Greenbaum CJ, Oyaski ML, et al. (2024) Evidence for C-peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes. Diabetes |
Russell WE, Moore DJ, Herold KC. (2023) Response to Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005-1013. Diabetes Care. 46: e210-e211 |
Ramos EL, Dayan CM, Chatenoud L, et al. (2023) Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes. The New England Journal of Medicine |
Libman I, Bingley PJ, Becker D, et al. (2023) Hydroxychloroquine in Stage 1 Type 1 Diabetes. Diabetes Care |
Sims EK, Geyer SM, Long SA, et al. (2023) High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment. Diabetologia |
Herold KC, Gitelman SE, Gottlieb PA, et al. (2023) Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function. Diabetes Care |
Delgado AL, Preston-Hurlburt P, Lim N, et al. (2023) Latent EBV impairs immune cell signaling and enhances the efficacy of anti-CD3 mAb in Type 1 Diabetes. Medrxiv : the Preprint Server For Health Sciences |
Russell WE, Bundy BN, Anderson MS, et al. (2023) Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care |
Caulfield JI, Aizenbud L, Perdigoto AL, et al. (2023) Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors. Journal For Immunotherapy of Cancer. 11 |